Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: A Danish nationwide prospective cohort study

Journal of Clinical Oncology

Volumn 31, Issue 18, 2013, Pages 2265-2272

  Sørensen, Gitte Vrelits ^a   Ganz, Patricia A ^d   Cole, Steven W ^d   Pedersen, Lars A ^a   Sørensen, Henrik Toft ^a,b   Cronin Fenton, Deirdre P ^a   Garne, Jens Peter ^c   Christiansen, Peer M ^a,b   Lash, Timothy L ^a,e   Ahern, Thomas P ^a,f  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Danish Breast Cancer Cooperative Group   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EMORY UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; METOPROLOL; PROPRANOLOL; RAMIPRIL; SOTALOL; VALSARTAN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; DENMARK; DRUG EXPOSURE; DRUG USE; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; LIPID SOLUBILITY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; VERY ELDERLY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; METHODOLOGY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; STATISTICS; TUMOR RECURRENCE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BREAST NEOPLASMS; DENMARK; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84882947561     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.9190     Document Type: Article

References (34)

1. Westfall T, Westfall D: Adrenergic agonists and antagonists, in Brunton L, Chabner B, Knollman B (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics (ed 12). New York, NY, McGraw-Hill, 2011
2. Sloan EK, Priceman SJ, Cox BF, et al: The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70: 7042-7052, 2010
3. Fitzgerald PJ: Is norepinephrine an etiological factor in some types of cancer? Int J Cancer 124: 257-263, 2009
4. Fitzgerald PJ: Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol 2:1-3, 2010
5. Yang EV, Sood AK, Chen M, et al: Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357-10364, 2006
6. Drell TL 4th, Joseph J, Lang K, et al: Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80:63-70, 2003
7. Powe DG, Voss MJ, Zänker KS, et al: Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1:628-638, 2010
8. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al: Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645-2652, 2011
9. Barron TI, Connolly RM, Sharp L, et al: Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol 29:2635-2644, 2011
10. Ganz PA, Habel LA, Weltzien EK, et al: Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: Results from the LACE cohort. Breast Cancer Res Treat 129:549-556, 2011
11. Ganz PA, Cole SW: Expanding our therapeutic options: Beta blockers for breast cancer? J Clin Oncol 29:2612-2616, 2011
12. Powe DG, Entschladen F: Targeted therapies: Using β-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 8:511-512, 2011
13. Shah SM, Carey IM, Owen CG, et al: Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population based retrospective cohort study? Br J Clin Pharmacol 72:157-161, 2011
14. George AJ, Thomas WG, Hannan RD: The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer 10:745-759, 2010
15. Sipahi I, Debanne SM, Rowland DY, et al: Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol 11:627-636, 2010
16. Fryzek JP, Poulsen AH, Lipworth L, et al: A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 97:231-236, 2006
17. The ARB Trialists Collaboration: Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 29:623-635, 2011
18. Pasternak B, Svanström H, Callréus T, et al: Use of angiotensin receptor blockers and the risk of cancer. Circulation 123:1729-1736, 2011
19. Chang CH, Lin JW, Wu LC, et al: Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study. J Clin Oncol 29:3001-3007, 2011
20. Chae YK, Valsecchi ME, Kim J, et al: Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29:585-593, 2011
21. Pedersen CB, Gøtzsche H, Møller JO, et al: The Danish Civil Registration System: A cohort of eight million persons. Dan Med Bull 53:441-449, 2006
22. Blichert-Toft M, Christiansen P, Mouridsen HT Danish Breast Cancer Cooperative Group–D-BCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 47:497-505, 2008
23. Møller S, Jensen M, Ejlertsen B, et al: The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG): Its 30-years experience and future promise. Acta Oncol 47:506-524, 2008
24. Kildemoes HW, Sørensen HT, Hallas J: The Danish National Prescription Registry. Scand J Public Health 39:38-41, 2011
25. Ahern TP, Pedersen L, Tarp M, et al: Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. J Natl Cancer Inst 103:1461-1468, 2011
26. Holmes MD, Chen WY, Li L, et al: Aspirin intake and survival after breast cancer. J Clin Oncol 28:1467-1472, 2010
27. Newcomb PA, Egan KM, Trentham-Dietz A, et al: Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 17:864-871, 2008
28. Andersen TF, Madsen M, Jørgensen J, et al: The Danish National Hospital Register: A valuable source of data for modern health sciences. Dan Med Bull 46:263-268, 1999
29. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
30. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. http://www.whocc.no
31. Allison PD: Survival Analysis Using SAS. Cary, NC, SAS Institute, 2010
32. Hansen PS, Andersen E, Andersen KW, et al: Quality control of end results in a Danish adjuvant breast cancer multi-center study. Acta Oncol 36: 711-714, 1997
33. Ewertz M, Jensen MB, Gunnarsdóttir KÁ, et al: Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29:25-31, 2011
34. Lokkegaard EL, Johnsen SP, Heitmann BL, et al: The validity of self-reported use of hormone replacement therapy among Danish nurses. Acta Obstet Gynecol Scand 83:476-481, 2004